We are live on ! Find out more
KYMR icon

Kymera Therapeutics
KYMR

121 hedge funds and large institutions have $1.39B invested in Kymera Therapeutics in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 48 increasing their positions, 38 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

219% more call options, than puts

Call options by funds: $30.2M | Put options by funds: $9.44M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

26% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 38

21% more capital invested

Capital invested by funds: $1.15B → $1.39B (+$243M)

5.75% more ownership

Funds ownership: 96.56% → 102.31% (+5.7%)

5% less funds holding

Funds holding: 127 → 121 (-6)

24% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 21

Holders
121
Holders Change
-6
Holders Change %
-4.72%
% of All Funds
1.95%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
16
Increased
48
Reduced
38
Closed
21
Calls
$30.2M
Puts
$9.44M
Net Calls
+$20.7M
Net Calls Change
+$20M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$44.8M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$31.5M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$21.3M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$13.9M
5
AG
Artal Group
Luxembourg
+$13.3M

Top Sellers

Rank Fund Capital Flow
1
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
-$23.8M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$10.5M
3
WA
Wasatch Advisors
Utah
-$6.09M
4
RG
Redmile Group
California
-$5.41M
5
American Century Companies
American Century Companies
Missouri
-$3.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
LSA
101
Leonteq Securities AG
Switzerland
$73.8K +$78.8K +2,955 New
Osaic Holdings
102
Osaic Holdings
Arizona
$66K – – –
MLICM
103
Metropolitan Life Insurance Company (MetLife)
New York
$59.4K +$2.53K +95 +4%
AAM
104
Advisors Asset Management
Colorado
$58.1K +$62K +2,327 New
Nisa Investment Advisors
105
Nisa Investment Advisors
Missouri
$52K – – –
Wells Fargo
106
Wells Fargo
California
$50.8K -$39.2K -1,470 -42%
Amundi
107
Amundi
France
$49.1K +$43.8K +1,642 New
Canada Life
108
Canada Life
Manitoba, Canada
$41K – – –
CUAMC
109
China Universal Asset Management Company
China
$13.9K +$1.92K +72 +15%
Dimensional Fund Advisors
110
Dimensional Fund Advisors
Texas
$7.82K +$2.69M +100,795 +47%
US Bancorp
111
US Bancorp
Minnesota
$7.36K +$7.87K +295 New
Daiwa Securities Group
112
Daiwa Securities Group
Japan
$6K +$1.89K +71 +47%
TWA
113
TCI Wealth Advisors
Arizona
$5.89K – – –
TC
114
Truvestments Capital
Florida
$1.47K – – –
BIA
115
Bell Investment Advisors
California
$524 – – –
AF
116
Allworth Financial
California
$474 -$80 -3 -14%
LC
117
Lindbrook Capital
California
$300 – – –
EI
118
Ellevest Inc
New York
$25 -$107 -4 -80%
PAMS
119
Pictet Asset Management (Switzerland)
Switzerland
– -$10.5M -482,001 Closed
GCM
120
Graham Capital Management
Connecticut
– -$2.2M -101,001 Closed
BNP Paribas Financial Markets
121
BNP Paribas Financial Markets
France
– -$1.65M -75,804 Closed
Millennium Management
122
Millennium Management
New York
– -$1.84M -69,085 Closed
TC
123
TwinBeech Capital
New York
– -$1.03M -47,468 Closed
HF
124
HRT Financial
New York
– -$760K -34,943 Closed
Man Group
125
Man Group
United Kingdom
– -$578K -26,550 Closed
2 3 4
5
6

KYMR Hedge Fund Activity: Q4 2022 in Review

121 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q4 2022, worth a combined $1.39B — up 21% from $1.15B a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of KYMR and 16 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 48 added.

The largest buyer was Avoro Capital Advisors, adding an estimated $44.8M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $23.8M.

  • 121 institutional investors held Kymera Therapeutics (KYMR) as of Q4 2022, down from 127 in Q3 2022.
  • Funds reported $1.39B of Kymera Therapeutics stock for Q4 2022, up 21% quarter-over-quarter.
  • 16 funds opened new Kymera Therapeutics positions in Q4 2022 and 21 closed out, a net change of -5 holders.
  • The largest Kymera Therapeutics buyer in Q4 2022 was Avoro Capital Advisors, an estimated $44.8M added.
  • The largest Kymera Therapeutics seller in Q4 2022 was Atlas Venture Life Science Advisors, an estimated $23.8M sold.

Based on aggregated 13F filings for Q4 2022.